Molecular Engineering Strategies Tailoring the Apoptotic Response to a MET Therapeutic Antibody
Open Access
- 21 March 2020
- Vol. 12 (3), 741
- https://doi.org/10.3390/cancers12030741
Abstract
The MET oncogene encodes a tyrosine kinase receptor involved in the control of a complex network of biological responses that include protection from apoptosis and stimulation of cell growth during embryogenesis, tissue regeneration, and cancer progression. We previously developed an antagonist antibody (DN30) inducing the physical removal of the receptor from the cell surface and resulting in suppression of the biological responses to MET. In its bivalent form, the antibody displayed a residual agonist activity, due to dimerization of the lingering receptors, and partial activation of the downstream signaling cascade. The balance between the two opposing activities is variable in different biological systems and is hardly predictable. In this study, we generated and characterized two single-chain antibody fragments derived from DN30, sharing the same variable regions but including linkers different in length and composition. The two engineered molecules bind MET with high affinity but induce different biological responses. One behaves as a MET-antagonist, promoting programmed cell death in MET “addicted” cancer cells. The other acts as a hepatocyte growth factor (HGF)-mimetic, protecting normal cells from doxorubicin-induced apoptosis. Thus, by engineering the same receptor antibody, it is possible to generate molecules enhancing or inhibiting apoptosis either to kill cancer cells or to protect healthy tissues from the injuries of chemotherapy.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (ID 21052)
- Ministero della Salute (ricerca corrente 2019)
This publication has 41 references indexed in Scilit:
- Activation of hepatocyte growth factor receptor, c-met, in renal tubules is required for renoprotection after acute kidney injuryKidney International, 2013
- Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent reviewExpert Opinion on Therapeutic Patents, 2011
- MET signalling: principles and functions in development, organ regeneration and cancerNature Reviews Molecular Cell Biology, 2010
- Monovalency Unleashes the Full Therapeutic Potential of the DN-30 Anti-Met AntibodyJournal of Biological Chemistry, 2010
- Agonist monoclonal antibodies against HGF receptor protect cardiac muscle cells from apoptosisAmerican Journal of Physiology-Heart and Circulatory Physiology, 2010
- Applications of single-chain variable fragment antibodies in therapeutics and diagnosticsBiotechnology Advances, 2009
- Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancerCellular Signalling, 2008
- Hepatocyte Growth Factor Gene Transfer to Alveolar Septa for Effective Suppression of Lung FibrosisMolecular Therapy, 2005
- PI3K/Akt and apoptosis: size mattersOncogene, 2003
- Specific Uncoupling of GRB2 from the Met ReceptorPublished by Elsevier BV ,1996